Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Northstar Neuroscience, Inc. (NASDAQOTCBB:NSTR)

CAPS Rating: No stars

A medical device company focused on developing and commercializing innovative neurostimulation therapies for a range of neurological diseases and disorders.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

7 Outperform
6 Underperform
 

All-Star Players

3 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTCBB:NSTR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

okletsinvest (22.08)
Submitted June 29, 2007

Northstar Neuroscience is a medical device company committed to providing neurostimulation therapies for people who suffer from stroke and other neurological disorders. The company's technology is designed to deliver electrical stimulation to the… More

NetscribeMedDevs (94.40)
Submitted March 01, 2007

Northstar Neuroscience is a medical device company committed to providing neurostimulation therapies for people who suffer from stroke and other neurological disorders. The company's innovative technology is designed to deliver targeted electrical… More

Recent Community Commentary

Read the most recent pitches from players about NSTR.

Recs

1
Member Avatar okletsinvest (22.08) Submitted: 6/29/2007 10:14:37 AM : Outperform Start Price: $2.17 NASDAQ OTC:NSTR Score: -297.37

Northstar Neuroscience is a medical device company committed to providing neurostimulation therapies for people who suffer from stroke and other neurological disorders. The company's technology is designed to deliver electrical stimulation to the outermost layer of the brain, called the cortex, in a process referred to as cortical stimulation.

This appears, at least on the surface (no pun intended), to be a safer 'experimental' therapy than the much publicized 'experimental' therapy of Deep Brain Stimulation.

So far results are promising and to my mind (again no pun intended), very exciting.

It's a risky investment for sure, as are most experimental therapies, but one I'm willing to take a chance on. Perhaps more out of hope (non financial), than anything else.

Recs

0
Member Avatar star60629 (30.80) Submitted: 5/4/2007 4:59:15 AM : Underperform Start Price: $2.49 NASDAQ OTC:NSTR Score: +299.92

Losing money like crazy,not expected to make profit in next 2 years. Huge insider holdings on options. NO insider buying. Hmmmm be patient and watch it go down.Great 2 year short holding.Sell now before it goes down more. PPP way too bloated.

Recs

1
Member Avatar NetscribeMedDevs (94.40) Submitted: 3/1/2007 8:23:43 AM : Underperform Start Price: $2.25 NASDAQ OTC:NSTR Score: +325.76

Northstar Neuroscience is a medical device company committed to providing neurostimulation therapies for people who suffer from stroke and other neurological disorders. The company's innovative technology is designed to deliver targeted electrical stimulation to the outermost layer of the brain, called the cortex, in a process referred to as cortical stimulation. It is also studying therapeutic applications for other neurological conditions including stroke-related aphasia and tinnitus.

Northstar has not generated any revenue in the past two years, and the same is expected to continue until late 2008, when it plans to launch its first product. The profitability of the company has also been negative and is expected to remain in red till 2009, one year later from the launch of its first product when it is expected to post some operating profits.

The company is expected to have a difficult path ahead because of the intense competition it faces in the industry. It is expected to face large challenges in developing operational skills and marketing expertise once it launches its first product. Moreover to launch its product it will have to build a strong sales force from scratch which is mountainous task in itself.

Moreover the company faces a huge risk of the failure of its product if the expected clinical results are not favorable enough to support its planned submission to the Food and Drug Administration. Due to the small size of the company and the heavy weight competitors in the market Medtronic, St. Jude, and Boston Scientific, which have many more resources at their disposal, it is not expected that Northstar will show promising results in the coming two years.

Leaderboard

Find the members with the highest scoring picks in NSTR.

Score Leader

NetscribeMedDevs

NetscribeMedDevs (94.40) Score: +325.76

The Score Leader is the player with the highest score across all their picks in NSTR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
NetscribeMedDevs 94.40 3/1/2007 Underperform 1Y $2.25 -99.87% +225.90% +325.76 2 Comments
qbit14 49.61 11/9/2007 Underperform NS $2.25 -99.87% +207.67% +307.54 0 Comment
dabg8 74.87 8/7/2007 Underperform 5Y $1.91 -99.84% +207.20% +307.04 0 Comment
witswagger 23.52 12/13/2007 Underperform NS $1.64 -99.82% +202.22% +302.03 0 Comment
star60629 30.80 5/4/2007 Underperform 5Y $2.49 -99.88% +200.04% +299.92 1 Comment
chipssahoy 71.95 6/29/2007 Underperform NS $2.19 -99.86% +199.75% +299.61 0 Comment
Tuomi 92.16 10/16/2007 Outperform 5Y $2.24 -99.87% +191.19% -291.06 0 Comment
Adizrael < 20 10/18/2007 Outperform 5Y $2.16 -99.86% +192.51% -292.37 0 Comment
okletsinvest 22.08 6/29/2007 7/23/2008 Outperform 1Y $2.17 -99.86% +197.51% -297.37 2 Comments
ClydeMan77 < 20 11/9/2007 Outperform 3Y $2.25 -99.87% +207.67% -307.54 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NSTR.